Loading…
No Handouts for Drug Advertisements Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2026 · third_quarter · Taxation/Internal Revenue Code
S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.
Client expense: Not reported · Firm income: $90,000
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Client expense: Not reported · Firm income: Not reported
Government targets: Food & Drug Administration (FDA)
2026 · second_quarter · Taxation/Internal Revenue Code
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Taxation/Internal Revenue Code
S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2026 · first_quarter · Health Issues
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Client expense: Not reported · Firm income: Not reported
2026 · first_quarter · Taxation/Internal Revenue Code
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Taxation/Internal Revenue Code
Issues related to corporate tax. H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Client expense: $3,320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2026 · first_quarter · Taxation/Internal Revenue Code
S. 1785/H.R. 3010 - The No Handouts for Drug Advertisements Act.
Client expense: Not reported · Firm income: $90,000
2025 · fourth_quarter · Taxation/Internal Revenue Code
S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Taxation/Internal Revenue Code
Issues related to corporate tax. H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Client expense: $2,270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2025 · fourth_quarter · Copyright/Patent/Trademark
Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act. S. 2658 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.
Client expense: Not reported · Firm income: $90,000
2025 · fourth_quarter · Health Issues
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2025 · third_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. S.43 Skinny Labels, Big Savings Act. H.R. 5526/S. 1954, the Biosimilar Red Tape Elimination Act. S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Taxation/Internal Revenue Code
Issues related to corporate tax. P.L. 119-21 - The One Big, Beautiful Bill Act H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Client expense: $2,150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2025 · third_quarter · Copyright/Patent/Trademark
Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act. S. 2658 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.
Client expense: Not reported · Firm income: $90,000
2025 · third_quarter · Health Issues
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2025 · second_quarter · Health Issues
S.483 (HR 1117) - Responsibility in Drugs Advertising Act S.229 - Drug Pricing Transparency for Consumers Act S.1785 (HR 3010) - No Handouts for Drug Advertising Act S.2068 (HR 4605) - End Prescription Drug Ads Now
Client expense: Not reported · Firm income: Not reported
Government targets: SENATE
2025 · second_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act H.R. 3160 & S. 1533, the PREVAIL Act S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025 S.43 Skinny Labels, Big Savings Act S. 1954, the Biosimilar Red Tape Elimination Act S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act S.1040 Drug Competition Enhancement Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Taxation/Internal Revenue Code
Issues related to corporate tax. P.L. 119-21 - The One Big, Beautiful Bill Act H.R. 3010/S. 1785 - No Handouts for Drug Advertisement Act
Client expense: $1,810,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE